AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 91 min read

UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120

UBS downgraded Revvity to Neutral from Buy and raised its price target to $140 from $120. The company recently acquired Human Cell Design SAS and presented at the Wells Fargo Healthcare Conference. Revvity's stock is currently trading at $123.85, with a 5-day change of -2.54% and a year-to-date change of +28.01%.

Original reporting
marketscreener.com
Published Sep 9, 2026, 1:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 3:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$RVTY
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade may trigger sell pressure, but the higher target hints at upside potential.

02

Market read

Analyst downgrade is a material catalyst for Revvity's near‑term price action.

03

What to watch

Recent acquisition of Human Cell Design may drive longer‑term growth.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

UBS issued a rating downgrade for Revvity, adjusting its price target.

Market effects

Sector

May affect other healthcare‑technology stocks as analysts reassess sector outlook.

Regional

Limited to US markets where Revvity trades.

Global

Low global impact.

Counterpoint

What could challenge this read

Target raise could signal upside potential despite downgrade.

Key entities

  • company
    Revvity, Inc.

    Healthcare‑technology firm receiving the downgrade.

  • analyst
    UBS

    Research firm providing the rating change.

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min
SEP 4
$RVTYMed

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity Inc. (RVTY) raised 2026 revenue guidance to $2.83-$2.86B and adjusted earnings to $5.30-$5.40 per share, citing 4%-5% organic growth. Diagnostics segment grew 11% in Q2. RVTY trades at 22.9X forward earnings, above industry and sector benchmarks. Software revenues fell 20% in Q2 but are expected to recover. Free cash flow reached $183.8M in Q2. Zacks Rank #3 (Hold) with mixed Style Scores.

tradingview.com2 min